BACKGROUND: Pralatrexate (Fotolyn(TM); Allos Therapeutics Inc.) is an antifolate dihydrofolate reductase (DHFR) inhibitor. We conducted a phase II study of pralatrexate with folic acid and B12 supplementation in patients with recurrent and/or metastatic head and neck squamous cell cancer (R/M HNSCC). PATIENTS AND METHODS: This was a single-arm, Simon optimal two stage phase II study. Patients with R/M HNSCC previously treated with chemotherapy were eligible. The study was initiated with a dosing schedule of pralatrexate 190 mg/m(2) biweekly on a 4-week cycle with vitamin supplementation. Due to toxicity concerns, the dosing was modified to 30 mg/m(2) weekly for 3 weeks in a 4-week cycle with vitamin supplementation. Radiologic imaging was to be obtained about every 2 cycles. RESULTS: Thirteen subjects were enrolled; 12 were treated. Seven of the twelve patients had previously received ≥2 lines of chemotherapy. The most common grade 3 toxicity was mucositis (3 patients). Seven patients did not complete two cycles of therapy due to progression of disease (4), toxicity (1), death (1), and withdrawal of consent (1). Two deaths occurred: one due to disease progression and the other was an unwitnessed event that was possibly related to pralatrexate. No clinical activity was observed. The median overall survival was 3.1 months. The study was closed early due to lack of efficacy. CONCLUSIONS: Pralatrexate does not possess clinical activity against previously treated R/M HNSCC. Evaluation of pralatrexate in other clinical settings of HNSCC management with special considerations for drug toxicity may be warranted.
BACKGROUND:Pralatrexate (Fotolyn(TM); Allos Therapeutics Inc.) is an antifolate dihydrofolate reductase (DHFR) inhibitor. We conducted a phase II study of pralatrexate with folic acid and B12 supplementation in patients with recurrent and/or metastatic head and neck squamous cell cancer (R/M HNSCC). PATIENTS AND METHODS: This was a single-arm, Simon optimal two stage phase II study. Patients with R/M HNSCC previously treated with chemotherapy were eligible. The study was initiated with a dosing schedule of pralatrexate 190 mg/m(2) biweekly on a 4-week cycle with vitamin supplementation. Due to toxicity concerns, the dosing was modified to 30 mg/m(2) weekly for 3 weeks in a 4-week cycle with vitamin supplementation. Radiologic imaging was to be obtained about every 2 cycles. RESULTS: Thirteen subjects were enrolled; 12 were treated. Seven of the twelve patients had previously received ≥2 lines of chemotherapy. The most common grade 3 toxicity was mucositis (3 patients). Seven patients did not complete two cycles of therapy due to progression of disease (4), toxicity (1), death (1), and withdrawal of consent (1). Two deaths occurred: one due to disease progression and the other was an unwitnessed event that was possibly related to pralatrexate. No clinical activity was observed. The median overall survival was 3.1 months. The study was closed early due to lack of efficacy. CONCLUSIONS:Pralatrexate does not possess clinical activity against previously treated R/M HNSCC. Evaluation of pralatrexate in other clinical settings of HNSCC management with special considerations for drug toxicity may be warranted.
Authors: Karen Kelly; Christopher G Azzoli; Petr Zatloukal; István Albert; Peter Y Z Jiang; David Bodkin; José Rodrigues Pereira; Erzsébet Juhász; Nicholas O Iannotti; Garry Weems; Tony Koutsoukos; Jyoti D Patel Journal: J Thorac Oncol Date: 2012-06 Impact factor: 15.609
Authors: X Pivot; S Wadler; C Kelly; R Ruxer; J Tortochaux; J Stern; D Belpomme; Y Humblet; C Domenge; N Clendeninn; A Johnston; C Penning; M Schneider Journal: Ann Oncol Date: 2001-11 Impact factor: 32.976
Authors: X León; R Hitt; M Constenla; A Rocca; R Stupp; A F Kovács; N Amellal; E H Bessa; J Bourhis Journal: Clin Oncol (R Coll Radiol) Date: 2005-09 Impact factor: 4.126
Authors: A A Forastiere; B Metch; D E Schuller; J F Ensley; L F Hutchins; P Triozzi; J A Kish; S McClure; E VonFeldt; S K Williamson Journal: J Clin Oncol Date: 1992-08 Impact factor: 44.544
Authors: E A Eisenhauer; P Therasse; J Bogaerts; L H Schwartz; D Sargent; R Ford; J Dancey; S Arbuck; S Gwyther; M Mooney; L Rubinstein; L Shankar; L Dodd; R Kaplan; D Lacombe; J Verweij Journal: Eur J Cancer Date: 2009-01 Impact factor: 9.162
Authors: J H Schornagel; J Verweij; P H de Mulder; F Cognetti; J B Vermorken; P Cappelaere; J P Armand; J Wildiers; A de Graeff; M Clavel Journal: J Clin Oncol Date: 1995-07 Impact factor: 44.544
Authors: X Pivot; E Raymond; B Laguerre; M Degardin; L Cals; J P Armand; J L Lefebvre; D Gedouin; V Ripoche; L Kayitalire; C Niyikiza; R Johnson; J Latz; M Schneider Journal: Br J Cancer Date: 2001-09-01 Impact factor: 7.640